Buy & Sell AMC ENTERTAINMENT HOLDINGS, INC. (AMC) – AMC ENTERTAINMENT HOLDINGS, INC. Price Today
Aura AI Summary
Key Stats
- $1.05BMarket Cap
- MediaSector
- -27.96%3M Drawdown
- $8.64BEnterprise Value
- 0.11%Dividend Yield
- 55% Buy | 45% SellTrading Activity
- 84 daysTypical Hold Time
AMC ENTERTAINMENT HOLDINGS, INC. (AMC) is currently valued at a market capitalization of $1.05B, with an enterprise value of $8.64B. Over the past 52 weeks, AMC ENTERTAINMENT HOLDINGS, INC. has traded between a low of $0.95 and a high of $4.01, highlighting its annual price range. Over the past three months, AMC ENTERTAINMENT HOLDINGS, INC. has recorded a drawdown of -27.96%, reflecting recent price volatility. AMC ENTERTAINMENT HOLDINGS, INC. offers a dividend yield of 0.11%, with the most recent dividend of $0.13 paid on 06 Mar 20. On average, investors hold AMC ENTERTAINMENT HOLDINGS, INC. for approximately 84 days, indicating typical investor behavior on the platform.
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Most Recent News
BlackRock increases voting rights in Renk Group AG to 4.44% as of May 7, 2026
BlackRock, Inc. has raised its total voting rights in Renk Group AG to 4.44% as of May 7, 2026, up from 3.63%. This increase includes direct and instrument-based voting rights. The disclosure was made in compliance with German securities trading regu...
BlackRock increases voting rights in Renk Group AG to 4.44% as of May 7, 2026.
BlackRock, Inc. has raised its total voting rights in Renk Group AG to 4.44% as of May 7, 2026, combining 2.95% direct and 1.49% through instruments. This increase from the previous 3.63% stake reflects BlackRock's growing influence in the company. T...
Inventiva to present two abstracts on lanifibranor at EASL Congress 2026 in Barcelona
Inventiva, a clinical-stage biopharmaceutical company, announced it will present two research abstracts on its drug candidate lanifibranor at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona. Lanifibranor is an or...
